La cadena de opciones muestra datos clave de las opciones de acciones de Eterna Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Eterna Therapeutics..

Eterna Therapeutics (NASDAQ:ERNA) Bolsa, Cadena de Opciones

Eterna Therapeutics

Eterna Therapeutics Inc is a biopharmaceuticals company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.

Eterna Therapeutics Inc

WIIM

IONQ

IonQ shares are trading higher after Craig-Hallum raised its price target on the stock from $22 to $45 while maintaining a Buy rating.

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Buy and maintains $80 price target.

News

Price Target

Reiteration

Analyst Ratings

ARWR

HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $80 Price Target

Looking for <a href="https://www.benzinga.com/trading-ideas/dividends">steady cash flow</a> in 2025? JPMorgan analysts have spotlighted four income-generating stock picks that offer dividend appeal and potential price upside. 
These are: Annaly Capital Management Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NLY#NYSE">NLY</a>), Corning Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>), Energy Transfer LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>) and HA Sustainable Infrastructure Capital Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HASI#NYSE">HASI</a>).
Here are the details on their top picks.
<h2 class="wp-block-heading">Annaly Capital</h2>
With a hefty forward dividend yield of 13.85% (per <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122024&amp;t=be2bearmibe3na1">Benzinga Pro</a> data), Annaly Capital shines as a beacon for income seekers. 
Analyst Richard Shane expects the mortgage REIT to benefit from a gradual yield curve steepening and rising MBS prices as quantitative tightening eases. 
Trading near $19.76, NLY is viewed as a stable dividend play, supported by mid-teen ROEs and rising interest spreads, according to the analyst. His price target for 2025 is $20.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/price-target/24/12/42615289/wall-streets-most-accurate-analysts-weigh-in-on-3-materials-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Materials Stocks Delivering High-Dividend Yields</a>
<h2 class="wp-block-heading">Corning</h2>
Known for its innovation in glass and fiber optics, Corning offers more than shiny screens. 
Its modest 2.38% yield may seem subdued, but JPMorgan's Samik Chatterjee says this tech titan is poised for high-single-digit revenue growth. 
Riding on data center demand, telecom recovery, and AI-driven innovation, Corning's stock—currently at $48.18—has room to climb to $60 by the end of 2025, the analyst says.
<h2 class="wp-block-heading">Energy Transfer</h2>
Pipeline powerhouse Energy Transfer is turning heads with a forward dividend yield of 7.06%. 
Analyst Jeremy Tonet sees untapped value in its discounted EV/EBITDA ratio compared to peers. 
With fundamentals like Permian egress and natgas logistics firing on all cylinders, ET, trading at $18.70, appears poised to reach Tonet's $23 target, presenting a compelling opportunity for midstream investors.
<h2 class="wp-block-heading">HASI</h2>
Sustainability meets income in Hannon Armstrong Sustainable Infrastructure Capital. HASI's 6.29% yield sweetens the deal for this eco-friendly investment.
JPMorgan's Mark Strouse predicts a brighter outlook thanks to its KKR partnership and investment-grade rating. With shares at $28.72, Strouse forecasts a $42 price by 2025 as HASI reduces its reliance on public capital raises and executes on stable spreads.
Whether you're chasing high yields or balanced growth, these four income plays could be the backbone of your 2025 portfolio. 
From Annaly's robust dividends to Corning's AI-driven potential, JPMorgan's picks are all about turning steady streams into rivers of returns.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/12/42612794/djt-stock-plummets-over-5-following-trumps-stake-transfer-heres-more">DJT Stock Plummets Over 5% Following Trump&#8217;s Stake Transfer: Here&#8217;s More</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

REIT

Dividends

Trading Ideas

Real Estate

Hannon Armstrong Sustainable Infrastructure Capital

HASI

4 Dividend Picks For 2025: JPMorgan's Top Income Stocks To Energize Your Portfolio

BCAB

BioAlta shares are trading lower after the company announced a $9.2 million registered direct offering of 9,679,158 shares at $1.19 per share.

Jefferies analyst Surinder Thind maintains Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) with a Hold and raises the price target from $355 to $385.

Jefferies Maintains Hold on Accenture, Raises Price Target to $385

Southern Copper's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCCO#NYSE">SCCO</a>) short percent of float has fallen 5.73% since its last report. The company recently reported that it has 6.73 million shares sold short, which is 7.73% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.85 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Southern Copper Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734710423_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Southern Copper has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Southern Copper's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Southern Copper's peer group average for short interest as a percentage of float is 2.85%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

SCCO

Peering Into Southern Copper's Recent Short Interest

PSQ Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSQH#NYSE">PSQH</a>) short percent of float has fallen 34.93% since its last report. The company recently reported that it has 1.13 million shares sold short, which is 3.95% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.96 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>PSQ Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734710418_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for PSQ Holdings has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing PSQ Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, PSQ Holdings's peer group average for short interest as a percentage of float is 3.68%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

PSQH

(PSQH) - Analyzing PSQ Holdings's Short Interest

Taiwan Semiconductor's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) short percent of float has fallen 3.33% since its last report. The company recently reported that it has 30.13 million shares sold short, which is 0.58% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.71 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Taiwan Semiconductor Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734710412_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Taiwan Semiconductor has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Taiwan Semiconductor's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Taiwan Semiconductor's peer group average for short interest as a percentage of float is 5.11%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Taiwan Semiconductor's Recent Short Interest

Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) has outperformed the market over the past 15 years by 5.0% on an annualized basis producing an average annual return of 16.65%. Currently, Boston Scientific has a market capitalization of $128.85 billion. 
Buying $100 In BSX: If an investor had bought $100 of BSX stock 15 years ago, it would be worth $1,007.02 today based on a price of $87.50 for BSX at the time of writing.
<h3>Boston Scientific's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734710410_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today

Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) stock is trading higher on Friday after Berkshire Hathaway Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) increased <a href="https://www.benzinga.com//node/42614904">its stake</a> in the company.
The Details: According to a Form 4 filing with the Securities and Exchange Commission, Berkshire purchased 8,896,890 shares in Occidental at an average price of $45.99.
The purchase costs Berkshire about $409 million in total.
Berkshire completed this purchase in stages, beginning on Dec. 17 and concluding on Dec. 19. The company now holds approximately a 28% stake in Occidental.
How To Buy Occidental Petroleum Shares
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Occidental Petroleum's case, it is in the Energy sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Related Link: <a href="https://www.benzinga.com/24/12/42616304/top-3-risk-off-stocks-that-may-collapse-this-month">Top 3 Risk Off Stocks That May Collapse This Month</a>
OXY Price Action: At the time of writing, Occidental stock is moving 5.22% higher at $47.70, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Photo via Shutterstock

Movers

What's Going On With Occidental Petroleum Shares Friday?

FNGR

FingerMotion shares are trading lower after the company announced a $5 million registered direct offering.

HC Wainwright &amp; Co. analyst Edward White reiterates InflaRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFRX#NASDAQ">IFRX</a>) with a Buy and maintains $8 price target.

IFRX

HC Wainwright & Co. Reiterates Buy on InflaRx, Maintains $8 Price Target

General

IIPR

CORRECTION: Innovative Industrial Properties shares are trading lower.

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYXS#NASDAQ">PYXS</a>) with a Buy and lowers the price target from $7 to $5.

PYXS

HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Lowers Price Target to $5

Molecular Templates Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) shares are trading lower by 60% to 13 cents during Friday&#8217;s session after the company announced it received a Nasdaq <a href="https://www.benzinga.com/pressreleases/24/12/g42603890/molecular-templates-announces-notice-of-delisting-and-failure-to-satisfy-continued-listing-rules">delisting notice</a>.
What To Know: Molecular Templates, a clinical-stage biopharmaceutical company developing cancer therapies, announced it has received notice from Nasdaq regarding the delisting of its securities. 
The Nasdaq Listing Qualifications Department cited the company's classification as a &#8220;public shell&#8221; and its failure to comply with key listing requirements. These include not filing its quarterly report for the third-quarter 2024 and failing to maintain the minimum $1.00 bid price for its stock.
Trading of Molecular Templates&#8217; common stock is set to be suspended on December 26. The company says it does not intend to appeal Nasdaq&#8217;s decision, and delisting will be formalized with the U.S. Securities and Exchange Commission following the suspension.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42615908/feds-preferred-inflation-gauge-falls-more-than-expected-markets-breathe-sigh-of-relief">Fed&#8217;s Preferred Inflation Gauge Falls More Than Expected: Markets Breathe Sigh Of Relief</a>
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, MTEM has a 52-week high of $4.12 and a 52-week low of $0.30.

MTEM

Why Molecular Templates (MTEM) Stock Is Down 60%

<a href="https://www.benzinga.com/topic/european-commission" target="_blank" rel="noreferrer noopener">The European Commission</a> granted unconditional approval Thursday for Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) to acquire Run:ai Labs Ltd, an Israel-based provider of GPU orchestration software.
The decision under the EU Merger Regulation concluded the acquisition would not raise competition concerns within the European Economic Area.
Nvidia, a U.S.-based leader in GPU technology for data centers, gaming and automotive applications, aims to integrate Run: ai&#8217;s software into its ecosystem. Run:ai specializes in software that helps organizations optimize and manage their artificial intelligence compute workloads across various environments, including on-premises and cloud platforms.
The commission&#8217;s investigation focused on whether the merger could harm competition in two critical markets: discrete GPUs for data centers and GPU orchestration software.
Although Nvidia holds a dominant position in the global market for data center GPUs, the inquiry determined the company lacks the technical ability and motivation to limit compatibility between its GPUs and competing software solutions. Similarly, Run:ai does not command a significant market share in GPU orchestration software, ensuring continued access to alternative providers for customers.
Super Micro Computer Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) and Dell Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) server products embedded Nvidia AI chips.
Some customers replicated serial numbers of the servers containing Nvidia chips purchased from Super Micro and attached them to other servers.
Also, smugglers altered the serial numbers in the server operating system.
Dell and Super Micro said they complied with the regulatory norms.
U.S. Big Tech giants have drawn intense regulatory scrutiny for allegedly trying to stifle fair competition by exploiting their influence.
In 2024, <a href="https://www.benzinga.com/government/24/11/41685490/nvidias-run-ai-acquisition-draws-european-regulatory-scrutiny-on-competition-concerns" target="_blank" rel="noreferrer noopener">U.S. regulatory bodies</a>, including the Department of Justice&#8217;s antitrust division, reviewed Nvidia&#8217;s potential dominance within the AI chip sector. The Federal Trade Commission was also examining investments by the Big Tech giants.
Nvidia&#8217;s plans to purchase British chip designer Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) succumbed to global regulatory opposition. Other significant acquisitions that failed to win regulatory approval included Broadcom Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) plans to acquire Qualcomm Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>).
Meanwhile, the U.S. Department of Commerce urged Nvidia&nbsp;to investigate how the company&#8217;s products reached China by flouting the semiconductor embargo, Reuters reported, citing The Information.
The Biden Administration slapped semiconductor sanctions on China by restricting its access to advanced artificial intelligence technology chips and equipment meant to produce the chips.
Nvidia urged leading distributors like Super Micro Computer and Dell to conduct spot checks of Southeast Asian customers.
Nvidia stock surged over 171% year-to-date. Investors can gain exposure to the stock through VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>) and Fidelity MSCI Information Technology Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTEC#NYSE">FTEC</a>).
NVDA Price Action:&nbsp;Nvidia stock is up 1.74% at $132.95 at publication Friday.
Photo: Shutterstock

Government

Regulations

Global

Tech

Media

AVGO

DELL

FTEC

NVDA

QCOM

SMCI

Nvidia Secures EU Approval For Run:ai Deal, US Probes China Export Breach

Jefferies analyst Laurence Alexander maintains FuelCell Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCEL#NASDAQ">FCEL</a>) with a Hold and lowers the price target from $15 to $8.4.

FCEL

Jefferies Maintains Hold on FuelCell Energy, Lowers Price Target to $8.4

YAAS

Youxin Technology Shares Resume Trade

Lululemon Athletica Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) shares initially dipped 2% to $366.00 Friday morning following Nike&#8217;s second-quarter earnings report and <a href="https://www.benzinga.com/24/12/42610441/nikes-new-ceo-says-we-lost-our-obsession-with-sport-as-he-rebukes-old-strategies-on-performance-marketing-isolation-of-wholesalers-aims-to-create-demand">strategic pivot</a> under its new CEO, Elliott Hill. Nike shares fell 5.5% to $72.86 Friday morning following the report.
What To Know: Nike's report highlighted better-than-expected earnings, with revenue reaching $12.35 billion, surpassing Wall Street estimates. 
However, Hill's <a href="https://www.benzinga.com/pressreleases/24/12/b42604084/nike-inc-reports-fiscal-2025-second-quarter-results">comments</a> about Nike regaining its dominance by reinvigorating its athlete-first approach, enhancing wholesale relationships, and leveraging value channels like Nike Value Stores to address inventory challenges signal a potential shakeup in market dynamics.
Lululemon has built its success on premium pricing, yoga-inspired apparel, and direct-to-consumer strategies. With Nike now pledging to &#8220;reinvest in brand stories&#8221; and reconnect with wholesale channels, analysts fear the competitive landscape could shift, drawing consumers away from Lululemon's niche. 
Nike's commitment to balancing digital and physical retail, as highlighted in the second-quarter <a href="https://www.benzinga.com/pressreleases/24/12/b42604084/nike-inc-reports-fiscal-2025-second-quarter-results">report</a>, could also pose risks to Lululemon&#8217;s omnichannel strategy.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42615908/feds-preferred-inflation-gauge-falls-more-than-expected-markets-breathe-sigh-of-relief">Fed&#8217;s Preferred Inflation Gauge Falls More Than Expected: Markets Breathe Sigh Of Relief</a>
<h2 class="wp-block-heading">How To Buy LULU Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>)'s case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, LULU has a 52-week high of $516.37 and a 52-week low of $226.19.

LULU

What's Going On With Lululemon (LULU) Stock?

Needham analyst Ami Fadia reiterates Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) from Hold to Hold.

NBIX

Needham Reiterates Hold on Neurocrine Biosciencesto Hold

Earnings week ahead: Walgreens Boots Alliance, Carnival, GameStop and more

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Eterna Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/erna-stock-quote/">ERNA</a>) just reported results for the first quarter of 2024.<ul><li>Eterna Therapeutics reported earnings per share of -$1.23.</li><li>The company reported revenue of $47,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/erna-stock-earnings-eterna-therapeutics-for-q1-of-2024/">ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q1 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Eterna Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/erna-stock-quote/">ERNA</a>) just reported results for the second quarter of 2024.<ul><li>Eterna Therapeutics reported earnings per share of -$1.02.</li><li>The company reported revenue of $47,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/erna-stock-earnings-eterna-therapeutics-for-q2-of-2024/">ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q2 2024

Eterna Therapeutics ( ($ERNA) ) has issued an update. Eterna Therapeutics Inc. has entered into an exclusive licensing and collaboration agreement ...

Eterna Therapeutics Strikes Key Deal for Disease-Fighting Tech

Eterna (ERNA) Therapeutics announced the completion of a comprehensive financial restructuring of the Company with the aim to accelerate its develo...

Eterna completes strategic financial restructuring

Eterna Therapeutics regains Nasdaq compliance

Eterna (ERNA) Therapeutics has regained compliance with Nasdaq for continued listing and that its stock will continue to trade on The Nasdaq Stock ...

Eterna regains compliance with Nasdaq

Eterna Therapeutics announces up to $1 million stock repurchase program

Eterna (ERNA) Therapeutics announced that its Board of Directors has authorized a stock repurchase program of up to $1M of the company's outstandin...

Eterna announces up to $1M stock repurchase program

Eterna (ERNA) Therapeutics announced it will investigate the ability of its lead iMSC-based cell therapy, ERNA-101, to induce and modulate antitumo...

Eterna launches research to evaluate ERNA-101

AGRX

AMPE

APTO

AQMS

AREC

ASTS

ATNM

AULT

AXDX

AYRO

BLRX

BZFD

CMCL

CTAS

CWCO

DARE

DCTH

DLNG

DNMR

DOMH

DOYU

DTIL

ERNA

ESLT

GLPG

GREE

HEPS

IDEX

ITRM

LGMK

LITB

MAXN

MDAI

NCNO

NVVE

OGEN

ORGS

OUST

PAYS

PAYX

PLBY

REKR

RKDA

SMTC

STIX

TIVC

VIOT

VRNT

VSTM

VUZI

WPRT

XELA

XXII

Health Care

Markets

Press Releases

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

Management

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M Locus

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success

Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing

Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program

Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate's (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models

Comments

Eterna Therapeutics

Eterna Therapeutics (ERNA) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL